Saad Z. Usmani, MD, FACP

Chief of Myeloma Service
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

Dr. Saad Usmani received his medical education at Allama Iqbal Medical College in Lahore, Pakistan. He completed a residency in internal medicine at Sinai-Grace Hospital/Wayne State University in Detroit, Michigan, and a fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington, Connecticut. He now serves as the Chief of Myeloma Service at Memorial Sloan Kettering Cancer Center and is Professor of Medicine at Weill Cornell Medical College, New York City.

Dr. Usmani is board certified in internal medicine, medical oncology, and hematology, and he is a fellow of the American College of Physicians. He holds membership and leadership roles on national/international committees, including the International Myeloma Working Group, the SWOG Myeloma Committee, the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the American Society of Transplant & Cellular Therapy, and the National Cancer Institute Myeloma Steering Committee. Dr. Usmani has served as the vice chair of the SWOG Myeloma Committee, and has served as chair for the ASH Scientific Committee on Plasma Cell Neoplasia, and the ASCO Scientific Committee on Plasma Cell Disorders He has received several international awards recognizing his clinical and translational research contributions to the field, including the Celgene Young Investigator Award for Clinical Research, COMY Award for Excellence in Myeloma Research, LLS Scholar in Clinical Research and the International Myeloma Society Bart Barlogie Award for Clinical and Translational Research. Dr. Usmani has authored/co-authored more than 190 peer-reviewed research manuscripts and 230 abstracts at national and international meetings. Active in clinical and translational research, Dr. Usmani has research interests focused on plasma cell disorders—in particular, high-risk multiple myeloma.

Last modified: April 4, 2022